DSGN PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

DSGN ▲ +6.54% at T+5d

LONG call ✓ call won +6.54% · α vs SPY +4.92% · entry $10.70 → $11.40

Next anchor: T+20d tomorrow

Currently $10.97 · +2.52% from $10.70 entry

Entry anchored
May 17, 2026
via day open

T+1d

-1.96%

call -1.96% · α -1.31%

$10.49

settled 26d ago

T+5d

+6.54%

call +6.54% · α +4.92%

$11.40

settled 22d ago

T+20d

—

call — · α —

—

tomorrow

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Design Therapeutics will announce Phase 1/2 RESTORE-FA trial data for DT-216P2 in Friedreich's ataxia on May 18, 2026. This is a binary catalyst for the stock, as positive data could validate the platform and drive significant upside, while negative data would be highly detrimental given the company's clinical-stage profile.

Actionable Insight

Traders should position for high volatility ahead of the May 18 data announcement. Positive Phase 1/2 data in Friedreich's ataxia could trigger a significant rally, while negative results would likely lead to a sharp decline. Consider straddle or strangle options strategies to capture the binary outcome.

Key Facts

Data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in Friedreich's ataxia will be announced on May 18, 2026.
Management will host a conference call and webcast at 8:00 a.m. ET on the same day.
Design Therapeutics is a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases.
The stock has a market cap of $898M and 92% analyst bullish rating.

Financial Impact

Binary event; positive data could drive 50-100% upside given early-stage biotech dynamics, while negative data could result in 50-80% downside.

market capstock price

Risk Factors

Negative or inconclusive Phase 1/2 data could lead to a severe stock price decline.
The company is clinical-stage with no approved products, making it highly dependent on this trial outcome.
Market expectations may already be priced in, limiting upside surprise.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

92% bullish (12 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3296269

6 reports for DSGN

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+5▲ +6.54%May 18, 2026

Filters

Reports for DSGN — sortable, filterable
	Type				Now
May 18, 2026 26d ago	8-K BULLISH ★ 7/10	$10.70 $11.40	▲ +6.54%	▲ +4.92%	$10.97 (+2.52%)
May 18, 2026 26d ago	Press Release BULLISH ★ 8/10	$10.70 $11.40	▲ +6.54%	▲ +4.92%	$10.97 (+2.52%)
May 17, 2026 26d ago	Press Release BULLISH ★ 8/10	$10.70 $11.40	▲ +6.54%	▲ +4.92%	$10.97 (+2.52%)
Apr 28, 2026 6w ago	Press Release BULLISH ★ 5/10	$15.79 $13.41	▼ −15.07%	▼ −18.18%	$10.97 (−30.53%)
Apr 23, 2026 7w ago	DEFA14A NEUTRAL ★ 3/10	$12.53 $13.60	▲ +8.54%	▲ +7.63%	$10.97 (−12.45%)
Apr 1, 2026 10w ago	3 NEUTRAL ★ 2/10	$11.23 $12.16	▲ +8.28%	▲ +4.66%	$10.97 (−2.32%)

US Market Status

Market Closed — Opens Mon (48h 51m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access